TheActualDataAre
AlwaysTheDataVille
There is was a big peer-reviewed paper that came out in the New England Journal of Medicine yesterday on the effectiveness of the massive roll out of the Pfizer mRNA-based vaccine in Israel.
Helen Branswell, who is an excellent science journalist, has an solid first pass summary STAT News. This is her lede:
Pfizer and BioNTech’s Covid-19 vaccine performed as well in the real world as it did in the clinical trial that led to its use, a large study conducted in Israel concluded.
The study, published Wednesday in the New England Journal of Medicine, is the largest to date assessing the effectiveness of the vaccine, comparing all illness, severe illness, and hospitalizations as well as deaths between 600,000 pairs of vaccinated and unvaccinated people...
One of the authors of the New England Journal paper, Marc Lipsitch, who is an epidemiologist at Harvard, jumped in on a twitter thread to make the following very important cautionary point in that regard:
So, again, and this time according to an expert who was involved in yesterday's peer-reviewed, published study, the science is not yet settled regarding the ability of the Pfizer vaccine to prevent viral transmission that generates both symptomatic infections (easier to track) and asymptomatic infections (harder to track).
That does not mean that things do not look promising, as Dr. Lipsitch himself thinks that the overall protection against viral transmission by the mRNA vaccine is 80% or more. It's just that he does not believe we actually have the data to be sure about the number:
________
Update...For more on the need for caution on claims of a specific rate of vaccine-mediated infection suppression (based on the data so far) see this very recent, solid piece by Megan Molteni in Wired.
No comments:
Post a Comment